Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSAfter a somewhat quiet end to 2022, deal activity remained muted in the first quarter of 2023 as macroeconomic uncertainty, rising interest rates and high inflation reduced companies' appetite for deal making.
Despite a flurry of bolt-on acquisitions announced at the start of the year and the first $40+ billion buyout signed since 2019, merger and acquisition (M&A) activity dropped off significantly in Q1 2023, with only 68 deals signed compared to 119 in Q1 2022. Similarly, partnering deal flow was suppressed 40% compared with Q1 2022, as pharma companies were more conservative about the types of assets they invested in. However, despite the slow start to the year, as the market begins to stabilize, there is hope that 2023 will be a far busier year overall for the industry.
M&A DEAL VOLUME ON THE DECLINE
Despite high hopes for an upturn in M&A activity, life sciences companies demonstrated even less of an appetite for M&A in Q1 2023, with the number of deals announced down by 43% in Q1 2023 compared to Q1 2022. This reduction in volume is likely a result of a variety of factors including macroeconomic headwinds, continued market volatility and declining valuations making it a challenging environment for negotiating parties to agree on a price. Interestingly, the aggregate and mean total value of all M&A deals signed in Q1 2023 increased more than three-fold compared with the same period in 2022 (Table 1).
To read more, please fill in your details on the left to download the article.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.